Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug sales
Pharma
Madrigal's MASH drug Rezdiffra 'blew away' expectations in Q3
Madrigal Pharmaceuticals potential blockbuster Rezdiffra racked up sales of $62 million in the third quarter, which routed Wall Street's expectations.
Kevin Dunleavy
Oct 31, 2024 3:24pm
Gardasil's troubles in China haunt Merck in Q3
Oct 31, 2024 1:25pm
Amgen reaps Horizon buyout rewards in Q3, preps biosim launches
Oct 31, 2024 7:50am
J&J leans on oncology growth drivers as Stelara sales slow
Oct 15, 2024 11:45am
Sandoz raises guidance after another quarter of sales growth
Aug 9, 2024 7:50am
The top 20 drugs by 2023 sales
May 28, 2024 3:00am
